⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
EN001
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-11 — Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia: Multi-center, randomized, double-blind, placebo-controlled Phase 1/2 trial launched to evaluate efficacy and safety of investigational agent EN001 in sarcopenia patients (trial registration, no readout yet). [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
11-sep-2026
novelty 3
per-area 3
strengthens